## 1,2-Bis(2-pyridyl)ethylene: A Versatile Ligand
**1,2-Bis(2-pyridyl)ethylene**, also known as **BPE**, is an organic compound with the formula **C12H10N2**. It is a **bidentate ligand**, meaning it can coordinate to metal ions through two donor atoms. In the case of BPE, these donor atoms are the two nitrogen atoms of the pyridine rings.
**Structure and Properties:**
* BPE has a **planar structure** with two pyridine rings connected by a double bond.
* It is a **white solid** with a melting point of 70-72 °C.
* BPE is **soluble** in common organic solvents like chloroform, dichloromethane, and ethanol.
**Importance in Research:**
BPE is a versatile ligand with numerous applications in research, particularly in **coordination chemistry**, **catalysis**, and **materials science**. Here are some key areas where it plays a significant role:
**1. Catalyst Design:**
* BPE forms **stable complexes with various transition metals**, such as palladium, platinum, nickel, and copper.
* These complexes are widely used as **catalysts in organic reactions**, including **cross-coupling reactions**, **hydrogenation**, and **C-H activation**.
* BPE's rigid structure and strong coordination ability make it an ideal ligand for promoting catalytic activity and selectivity.
**2. Supramolecular Chemistry:**
* BPE can self-assemble into **supramolecular structures** with various metal ions and organic molecules.
* These structures exhibit interesting properties like **luminescence**, **conductivity**, and **non-linear optics**, making them promising candidates for applications in materials science.
**3. Metal-Organic Frameworks (MOFs):**
* BPE can act as a linker in the synthesis of **MOFs**, which are porous materials with high surface area and potential for various applications like gas storage, separation, and catalysis.
* BPE's rigid structure and multiple coordination sites make it a suitable building block for creating diverse and functional MOFs.
**4. Sensor Development:**
* BPE can be incorporated into **luminescent sensors** for detecting various analytes, including metal ions, organic molecules, and biological species.
* Its ability to bind to metal ions and its sensitivity to environmental changes make it a valuable component in sensor design.
**5. Pharmaceutical Research:**
* Some studies suggest BPE derivatives could possess **pharmacological activity**, such as anti-cancer and antimicrobial properties.
* Further research is needed to explore the potential of BPE in medicinal chemistry.
**Overall, 1,2-bis(2-pyridyl)ethylene is a versatile ligand with a wide range of applications in chemistry and materials science. Its unique properties make it a valuable tool for developing new catalysts, functional materials, and sensors with diverse applications.**
1,2-bis(2-pyridyl)ethylene: a drug metabolizing enzyme inducer
ID Source | ID |
---|---|
PubMed CID | 5374802 |
CHEMBL ID | 67376 |
SCHEMBL ID | 229328 |
MeSH ID | M0523388 |
Synonym |
---|
2-(2-pyridyl-2-vinyl)pyridine, trans- |
13341-40-7 |
einecs 215-866-7 |
nsc 9489 |
nsc-9489 |
1437-15-6 |
nsc9489 |
mls000737910 , |
2-(2-pyridyl-2-vinyl)pyridine, trans |
pyridine,2,2'-(1,2-ethenediyl)bis-(e)- |
1,2-bis(2-pyridyl)ethylene |
pyridine, 2,2'-(1,2-ethenediyl)bis- |
1,2-bis(2-pyridyl)ethylene, 97% |
smr000528086 |
B1131 , |
1,2-di(2-pyridyl)ethylene |
CHEMBL67376 , |
2,2'-ethene-1,2-diyldipyridine |
bdbm50279890 |
2-[(e)-2-pyridin-2-ylvinyl]pyridine |
2-[(e)-2-pyridin-2-ylethenyl]pyridine |
NCGC00246902-01 |
HMS2886B23 |
AE-641/02354001 |
AKOS015913730 |
pyridine, (1,2-ethenediyl)bis- |
SCHEMBL229328 |
2,2'-vinylenedipyridine |
pyridine, 2,2'-vinylenedi- |
HKEOCEQLCZEBMK-BQYQJAHWSA-N |
2-(2-(2-pyridinyl)ethenyl)pyridine |
mfcd00006356 |
AS-62215 |
2-[2-(pyridin-2-yl)ethenyl]pyridine |
2,2'-trans-vinylenedipyridine |
J-007862 |
CS-0204870 |
1,2-di(pyridin-2-yl)ethene |
Q63408675 |
(e)-1,2-bis(2-pyridinyl)ethene |
(e)-1,2-di(pyridin-2-yl)ethene |
BAA43715 |
2,2'-(1e)-1,2-ethenediylbis[pyridine] |
DTXSID60871839 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 28.1838 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 21.3313 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 18.3489 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 79.4328 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
IDH1 | Homo sapiens (human) | Potency | 10.3225 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 1.1220 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
serine-protein kinase ATM isoform a | Homo sapiens (human) | Potency | 0.3162 | 0.7079 | 25.1119 | 41.2351 | AID485349 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 2.8184 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 79.4328 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 2.5119 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 26.6795 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
geminin | Homo sapiens (human) | Potency | 23.1093 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 14.1254 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (30.00) | 29.6817 |
2010's | 6 (60.00) | 24.3611 |
2020's | 1 (10.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.97) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |